Published in TB and Outbreaks Week, April 15th, 2003
RIF "releases smaller quantities of lipoteichoic acids (LTAs) from Streptococcus pneumoniae than ceftriaxone (CRO)," explained Joachim Gerber and colleagues at Georg-August University in Gottingen. "Due to the rapid development of resistance, RIF cannot be used as a single agent for therapy of bacterial meningitis."
However, RIF pretreatment reduced the amount of streptococcal LTAs released during CRO therapy, Gerber and coauthors found.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week